X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (1y) (2018 - 2025)
X4 Pharmaceuticals (XFOR) Net Cash Flow Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 53.46% |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn | 455.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 455.40% |
| Sep 30, 2025 | 160.92% |
| Jun 30, 2025 | -102.24% |
| Mar 31, 2025 | 60.16% |
| Dec 31, 2024 | -27.70% |
| Sep 30, 2024 | 5.29% |
| Jun 30, 2024 | 220.90% |
| Mar 31, 2024 | -35.87% |
| Dec 31, 2023 | -178.24% |
| Sep 30, 2023 | -261.51% |
| Jun 30, 2023 | 187.78% |
| Mar 31, 2023 | -87.28% |
| Dec 31, 2022 | 654.31% |
| Sep 30, 2022 | 274.92% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | -142.37% |
| Dec 31, 2021 | 154.08% |
| Sep 30, 2021 | -23.60% |
| Jun 30, 2021 | -77.21% |
| Mar 31, 2021 | 425.29% |